首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   74021篇
  免费   5324篇
  国内免费   1213篇
耳鼻咽喉   493篇
儿科学   3629篇
妇产科学   1118篇
基础医学   7666篇
口腔科学   1037篇
临床医学   9528篇
内科学   10763篇
皮肤病学   770篇
神经病学   2288篇
特种医学   1691篇
外国民族医学   3篇
外科学   9524篇
综合类   10681篇
预防医学   11331篇
眼科学   311篇
药学   6249篇
  57篇
中国医学   1486篇
肿瘤学   1933篇
  2023年   1118篇
  2022年   1809篇
  2021年   2846篇
  2020年   3284篇
  2019年   2500篇
  2018年   2396篇
  2017年   2516篇
  2016年   2505篇
  2015年   2793篇
  2014年   5142篇
  2013年   5527篇
  2012年   4864篇
  2011年   5115篇
  2010年   3829篇
  2009年   3607篇
  2008年   3490篇
  2007年   3497篇
  2006年   3277篇
  2005年   2880篇
  2004年   2402篇
  2003年   2017篇
  2002年   1506篇
  2001年   1370篇
  2000年   1133篇
  1999年   1047篇
  1998年   822篇
  1997年   750篇
  1996年   637篇
  1995年   658篇
  1994年   635篇
  1993年   535篇
  1992年   505篇
  1991年   441篇
  1990年   367篇
  1989年   354篇
  1988年   295篇
  1987年   252篇
  1986年   242篇
  1985年   284篇
  1984年   207篇
  1983年   150篇
  1982年   204篇
  1981年   150篇
  1980年   108篇
  1979年   94篇
  1978年   77篇
  1977年   76篇
  1976年   71篇
  1975年   33篇
  1973年   34篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
摘要: 目的 系统评价注射用头孢哌酮钠/舒巴坦钠(商品名:舒普深)在中国治疗临床感染的有效性和安全性。 方法 系 统检索万方、中国知网、维普、SinoMed、PubMed和Cochrane Library数据库,收集1978年至2019年7月4日公开发表的关于头孢 哌酮/舒巴坦在中国治疗临床感染方面的文献,按照纳入排除标准进行筛选,使用Stata 15.0和SAS 9.4软件进行荟萃(Meta)分析。 主要结局指标包括临床有效率与痊愈率,次要结局指标包括细菌清除率(株)与不良事件发生率。 结果 最终纳入110篇文献,其 中有82篇、87篇分别纳入有效率和痊愈率的Meta分析。结果显示,头孢哌酮/舒巴坦治疗临床感染的总有效率为80.3% [95%置信 区间(CI): 77.4%~83.0%],痊愈率为50.1% (95%CI: 45.1%~55.1%)。共38项研究报告了细菌清除率,结果显示细菌清除率为81.1% (95%CI: 76.9%~84.9%)。62篇文献报告治疗中发生的不良事件例数,合计不良事件的发生率为7.4% (95%CI: 6.1%~8.9%),包括 血液系统不良事件、胃肠道不良事件、肝肾功能损害及皮肤不良事件等。与其他对照药物相比,头孢哌酮/舒巴坦治疗临床感染 的有效性和安全性良好。 结论 头孢哌酮/舒巴坦的临床应用效果较为可观,对治疗临床感染具有较高的价值,安全性好。但 临床应注意合理用药,加强对头孢哌酮/舒巴坦的不良事件监测,减少不良事件。  相似文献   
2.
Approximately 10%-20% of the cases of acute pancreatitis have acute necrotizing pancreatitis. The infection of pancreatic necrosis is typically associated with a prolonged course and poor prognosis. The multidisciplinary, minimally invasive “step-up” approach is the cornerstone of the management of infected pancreatic necrosis (IPN). Endosonography-guided transmural drainage and debridement is the preferred and minimally invasive technique for those with IPN. However, it is technically not feasible in patients with early pancreatic/peripancreatic fluid collections (PFC) (< 2-4 wk) where the wall has not formed; in PFC in paracolic gutters/pelvis; or in walled off pancreatic necrosis (WOPN) distant from the stomach/duodenum. Percutaneous drainage of these infected PFC or WOPN provides rapid infection control and patient stabilization. In a subset of patients where sepsis persists and necrosectomy is needed, the sinus drain tract between WOPN and skin-established after percutaneous drainage or surgical necrosectomy drain, can be used for percutaneous direct endoscopic necrosectomy (PDEN). There have been technical advances in PDEN over the last two decades. An esophageal fully covered self-expandable metal stent, like the lumen-apposing metal stent used in transmural direct endoscopic necrosectomy, keeps the drainage tract patent and allows easy and multiple passes of the flexible endoscope while performing PDEN. There are several advantages to the PDEN procedure. In expert hands, PDEN appears to be an effective, safe, and minimally invasive adjunct to the management of IPN and may particularly be considered when a conventional drain is in situ by virtue of previous percutaneous or surgical intervention. In this current review, we summarize the indications, techniques, advantages, and disadvantages of PDEN. In addition, we describe two cases of PDEN in distinct clinical situations, followed by a review of the most recent literature.  相似文献   
3.
目的系统评价俯卧位通气对静脉-静脉体外膜肺氧合(VV-ECMO)支持的急性呼吸窘迫综合征(ARDS)患者病死率的影响。 方法计算机检索Medline、荷兰医学文摘Embase、Cochrane临床试验数据库、万方数据库及中国知网数据库从2002年1月至2022年1月关于VV-ECMO支持ARDS期间使用俯卧位通气的随机对照研究或观察性研究。试验组为俯卧位通气患者,对照组为仰卧位通气患者。由2名研究人员独立进行筛选文献、提取文献资料及评估方法学质量后,采用RevMan 5.3软件进行Meta分析。 结果最终纳入14项研究,共计1 880例患者,其中试验组869例,对照组1 011例。Meta分析显示,与对照组比较,试验组VV-ECMO支持的ARDS患者的28 d病死率[相对危险度(RR)=0.59,95%置信区间(CI)(0.43,0.80),Z = 3.41,P = 0.000 7]及住院病死率[RR = 0.73,95%CI(0.66,0.81),Z = 5.86,P < 0.000 01]均显著降低;但两组患者间其他病死率(30 d、60 d、90 d、ICU、6个月病死率)的比较,差异无统计学意义[RR = 0.80,95%CI(0.61,1.05),Z = 1.60,P = 0.11]。 结论俯卧位通气能够降低VV-ECMO支持的ARDS患者28 d病死率以及住院病死率。  相似文献   
4.
目的 探讨集束化干预策略联合闭环管理模式对ICU多重耐药菌感染的防控效果。方法选取2020年1~12月EICU住院患者275例作为对照组,实施常规管理;2021年1~10月EICU住院患者239例作为观察组,在常规管理基础上实施集束化干预策略联合闭环管理。结果实施后,观察组多重耐药菌感染发生率明显低于对照组;患者住院日显著低于对照组,4项护理措施执行率(隔离标识、手卫生、环境消毒、医务人员相关知识知晓)、病原学送检率显著高于对照组(均P<0.05)。结论集束化干预联合信息化闭环管理可有效降低EICU多重耐药菌感染发生率。  相似文献   
5.
6.
7.
8.
Tsukamurella species are obligate aerobic, gram-positive, weak acid-fast, nonmotile bacilli. They are found in various environments, such as soil, water, sludge, and petroleum reservoir wastewater, and belong to the order Actinomycetales. In 2016, there was a reclassification of species within the genus Tsukamurella, merging the species Tsukamurella tyrosinosolvens (T. tyrosinosolvens) and Tsukamurella carboxydivorans. Tsukamurella species are clinically considered to be a rare opportunistic pathogen, because most reported cases have been related to bacteremia and intravascular prosthetic devices and immunosuppression. To date, it has been isolated only from human specimens, and has always been associated with clinical disease; human infections are very rare. Reported infections have included pneumonia, brain abscesses, catheter-related bloodstream infections, ocular infections, bacteremia, and sepsis presenting with septic pulmonary emboli in patients who are immunocompromised. To date, there is no commercially available test for identification. On the other hand, sequence-based identification, including matrix-assisted laser desorption ionization time-of-flight mass spectrometry, is an alternative method for identifying clinical isolates that are either slow growers or difficult to identify through biochemical profiling. The golden standards for diagnosis and optimal management still remain to be determined. However, newer molecular biological techniques can provide accurate identification, and contribute to the appropriate selection of definitive therapy for infections caused by this organism. Combinations of several antimicrobial agents have been proposed for treatment, though the length of treatment for infections has yet to be determined, and should be individualized according to clinical response. Immunocompromised patients often experience severe cases due to infection, and life-threatening T. tyrosinosolvens events associated with dissemination and/or failure of source control have occurred. Favorable prognoses can be achieved through earlier identification of the cause of infection, as well as successful management, including appropriate antibiotic therapy together with source control. Further analyses of similar cases are required to establish the most adequate diagnostic methods and treatment regimens for infections.  相似文献   
9.
10.
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号